Diğer Ürünler
Skip Navigation Links.


Bone metabolism

In the Western World, approx. 8 –10 % of the population suffer from osteoporosis – often without knowing it since initially the symptoms are interpreted as normal symptoms of old age. The number of undiagnosed patients with osteoporosis-related fractures is estimated to be about 40 % (Source: current Emnid study).

Osteoporosis is diagnosed too rarely, so that only 30 % of the women suffering from osteoporosis are adequately treated (Source: World Osteoporosis Day 2008).

The increasing number of drugs available for treatment of bone diseases requires the use of more rapid and predictive methods to assess therapy efficacy. While detectable and significant changes in bone mineral density (BMD) take 18 to 24 months to develop, bone turnover markers have been shown to detect changes in bone tissue within 3 – 6 months after starting anti-resorptive therapy.

Therefore, measurement of bone turnover markers is increasingly recommended as a key component of therapy management.


YKL-40 Antibodies >>

Cat-No. Productname
8012 BAP MicroVue™ Quidel®
BI-20432 Cathepsin K
8003 CICP/PICP MicroVue™ Quidel®
8009 Creatinine (Quidel®)
BI-20412 Dickkopf-1(DKK-1)
8007 DPD (Quidel®)
8022 Helical Peptide (Quidel®)
9021 NTX-Serum (Osteomark®)
9006 NTX-Urine (Osteomark®)
BI-20403 OPG
8034 OPG, Human (Quidel®)
KT-809 Osteocalcin (1-43/49) N-MID human
8002 Osteocalcin Intact, Human (Quidel®)
50-1300 Osteocalcin, Mouse
50-1500 Osteocalcin, Rat
TE 5000 Osteopontin, Human
TE 6000 Osteopontin, Mouse
TE 7000 Osteopontin, Rat
8004 PYD & DPD MicroVue™ Quidel®
8010 PYD and DPD (Quidel®)
8006 PYD MicroVue™ Quidel®
8019 PYD Serum (Quidel®)
TE1023 Sclerostin TECO®
BI-20452 sRANKL, Human, high sensitive
8032 Total DPD (Quidel®)
8036 TRAP5b, Human (Quidel®)
8042 TRAP5b, Rat